In the BioHarmony Drug Report Database

"Preview" Icon

Cedazuridine

Inqovi (cedazuridine) is a small molecule pharmaceutical. Cedazuridine was first approved as Inqovi on 2020-07-07. It is known to target cytidine deaminase. Inqovi’s patents are valid until 2030-08-22 (FDA).

 

Trade Name

 

Inqovi
 

Common Name

 

cedazuridine
 

ChEMBL ID

 

CHEMBL3237547
 

Indication

 

 

Drug Class

 

Antivirals, antineoplastics (uridine derivatives)

Image (chem structure or protein)

Cedazuridine structure rendering